Anti-cancer properties of *Escherichia coli* Nissle 1917 against HT-29 colon cancer cells through regulation of Bax/Bcl-xL and AKT/PTEN signaling pathways

Siamak Alizadeh 1,2, Abolghasem Esmaeili 1*, Yadollah Omidi 2,3

1 Department of Cell and Molecular Biology & Microbiology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, Iran
2 Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran
3 Department of Pharmaceutics, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran

**Abstract**

Objective(s): Chemotherapies used to treat colon cancer might often fail due to the emergence of chemoresistance and side effects. *Escherichia coli* Nissle 1917 (EcN) is a beneficial probiotic, whose molecular mechanisms in the prevention of colon cancer are yet to be fully understood. The present study assessed the anti-cancer effects of EcN treatments in human colorectal cancer, HT-29 cell line, with the analysis of related mechanisms.

Materials and Methods: The co-culture conditioned-media (CM) of EcN with adenocarcinoma HT-29 cells and heat-inactivated bacteria (HIB) were applied for the treatment of the HT-29 cells. To study the inhibition potential of CM and HIB on cancer cell viability of AKT1/molecular mechanisms were implemented, including DAPI-staining and DNA ladder assays, flow cytometry and Real-time quantitative PCR (qPCR), as well as Western blotting analyses.

Results: Our results indicated that EcN could elicit apoptotic impacts on the colon cancer HT-29 cells by up-regulating PTEN and Bax and down-regulating AKT1 and Bcl-xL genes.

Conclusion: Based on our findings, EcN is proposed as a useful supplemental probiotic treatment against colon cancer.

Introduction

Colon cancer is the third leading reason for cancer-associated death worldwide (1). Various determinant factors may be involved in the initiation and progression of colon cancer, including genetic and/or epigenetic mutations and environmental factors (e.g., lifestyle and diet, health and disease, and pharmaco therapy regimen) (2). A wide range of studies supports the role of microbiota (i.e., colonic microflora) in the etiology of colorectal cancer. Therefore, the selective stimulation or deactivation of specific types of microbiota in the gut with beneficial roles in the body may influence the occurrence of colorectal cancer (3). These bacteria may intriguingly have a potential role in modulating, altering, and improving the gut microflora in colon cancer (3, 4). EcN is one of the most-studied probiotic strains, which may be used as edible probiotic for a broad range of gastrointestinal (GI) disorders, including ulcerative colitis (UC), inflammatory bowel disease (IBD), Crohn’s disease (CD), and other GIT-related diseases (4). Probiotics are nonpathogenic microorganisms that beneficially affect their hosts when used in an adequate amount (5). The unique features of the strain are (i) lack of virulence, (ii) antagonism toward the other pathogens, (iii) immunomodulatory properties, and (iv) survival factors and probiotic potential. These features make the strain a good and safe candidate for the treatment of GI disorders (6). Recently, EcN has successfully been used as one of the safest carriers for the therapeutic molecules both in vitro and in vivo (6). Although plenty of studies have been carried out in terms of the beneficial effects of EcN against intestinal diseases, still, limited information is available regarding the signaling pathways and molecular mechanisms involved in the anti-cancer effects of EcN in colorectal cancer (CRC). In this context, a deep understanding of the role of various signaling pathways that are always altered during cancer progression absolutely influences the successful treatment of cancers (7). Of the different signaling pathways, Bax and Bcl-xL involved in the intrinsic apoptosis pathway have pivotal roles in cancer development and aggressiveness (8). Moreover, the PI3K/AKT signaling pathway and expression of AKT can particularly affect a variety of cellular processes, resulting in reduced apoptosis, enhanced cell growth, and proliferation. These signaling routes are negatively controlled by a tumor suppressor protein known as phosphatase and tensin homolog (PTEN) (9). Increased activation of AKT signaling and down-regulation of PTEN were reported to be associated with 60–70% of the human colon cancer patients (10). The human colon adenocarcinoma cell line HT29 represents a valuable model for attachment and mechanistic studies due to their similarities with enterocytes and mucin
secretion ability. In fact, the mucosal layer created by this cell line seems to play a major role in the adhesion of bacteria or bacterial compounds to the epithelial surface (11). Therefore, this study was designed to investigate the potential of EcN or EcN-derived factors (CM and HIB) on the eradication of HT-29 colon cancer cells. Moreover, considering the importance of the aforementioned signaling paths and the therapeutic potential of EcN in GI disorders, we followed the controlling impact(s) of EcN on the initiation and progression of colorectal cancer throughout the investigation of AKT, PTEN, Bax, and Bcl-xL expressions.

Materials and Methods

Reagents
Colon adenocarcinoma cells (HT-29) were obtained from the National Cell Bank of Iran (Pasteur Institute, Tehran, Iran). RPMI-1640 media, fetal bovine serum (FBS) were purchased from Invitrogen™ Gibco (Paisley, UK). TRizol® Reagent, MMLV Reverse Transcriptase, RNase inhibitor, and dNTP were obtained from Thermo Fisher Scientific (Waltham, MA, USA). SYBR Green PCR Master Mix was obtained from Applied Biosystems (Foster City, CA, USA). The apoptosis detection kit, annexin V-fluorescein isothiocyanate (FITC), was purchased from eBioscience (Waltham, MA, USA). DAPI (4, 6-diamidino-2-phenylindole) was attained from Sigma-Aldrich Co. (Poole, UK), PTEN (A2B1): sc-7974, AKT1 (B-1): sc-5298, Bax (B-9): sc-7480 and GAPDH (6C5): sc-32233 were from Santa Cruz Biotechnology (Dallas, TX, USA).

Bacterial strain and cell culture
Escherichia coli Nissle 1917 (serotype O6:K5:H1) was extracted from the probiotic preparation Mutaflor® as its active component. HT-29 cells were cultured at a seeding density of 2.0×10⁴ cells/cm² in 6-well plates containing 2 ml of RPMI-1640 media, which was supplemented with 10% FBS and penicillin/streptomycin (0.1 mg/ml) and kept in a humidified incubator with 5% CO₂. Upon reaching 60–70% confluence, the cultivated cells were first washed with PBS (×3). The cells were then treated with the conditioned media (CM) and heat-inactivated bacteria (HIB).

Conditioned-media and heat-inactivated bacteria preparation
For the preparation of CM, the overnight culture of bacteria (EcN) in LB broth was centrifuged at 2800 ×g for 5 min. Then, the bacterial pellets were washed with PBS (×3). The HT-29 cells cultivated in RPMI medium without antibiotics were introduced to about 0.5 McFarland concentrations of bacteria for 4–6 hr. Then, co-culture media was centrifuged at 2800 ×g for 5 min and filtered using a 0.2 µm filter. The resulting media was considered as CM and exploited for the treatment of the HT-29 cells at different time points. For production of HIB, 0.5 McFarland concentrations of an overnight culture of bacteria were heated at 70 °C for 10 min, then transferred to -70 °C for 5 min. These actions were repeated three times, and then the resultant bacteria were subjected to LB medium to confirm the lack of bacterial growth.

MTT assay
The MTT assay was utilized to determine the probable toxicity of EcN against CRC (12). Briefly, the confluent HT-29 cells in the 96-well plate were treated with a series of designated concentrations of EcN for 24 and 48 hr. Subsequently, an equal volume of DMSO (0.5%) and MTT solution (5 µg/ml PBS) were included in the control and test groups. The plate was further incubated at 37 °C. Then, the formed formazan crystals through the oxidation of MTT dye were dissolved in 200 µl of DMSO per well. Finally, the absorbance of the samples was read at 570 nm using an ELX808 UV universal microplate reader (BioTek Instruments Inc., Vermont, USA). The experiments were performed in triplicate.

Detection of apoptotic cells by DNA fragmentation and DAPI staining assays
DNA ladder test was used for the evaluation of DNA fragmentation and detection of apoptotic cells in the treated HT-29 cells by means of a method established previously (13). For DAPI staining, the HT-29 cells were seeded in 6-well plates containing coverslips and treated with CM or HIB for 48 hr. Afterward, to fix the cells, they were incubated with 4% paraformaldehyde for 10 min. Then, the fixed cells were washed (×3) with PBS. The samples were permeabilized by means of 0.1% Triton X-100 for 10 min. After washing (×3) with PBS, the samples were stained using 4′, 6-diamidino-2-phenylindole (DAPI) at room temperature for 5 min. The morphology of the cells was assessed using the IX81 inverted fluorescent microscope (Olympus Corp., Tokyo, Japan). The images of the cells were acquired with an Olympus DP72 digital camera.

Flow cytometry analysis
The annexin V-FITC apoptosis detection kit was exploited to detect any emergence of the apoptosis and/or necrosis in the HT-29 cells treated with CM or HIB. Following the manufacturer’s protocol, the samples were prepared (eBioscience, San Diego, CA, USA). Briefly, cells treated with CM or HIB for 48 hr (OD600: 1.0) were harvested and centrifuged at 111 ×g for 5 min. Then, the cell pellets were washed with PBS and resuspended in the annexin V binding buffer. The cells were stained using annexin V-FITC for 15 min, and then, incubated at room temperature in the dark. To resuspend the cells, the PI binding buffer was used and the cells were prepared for the analysis of apoptosis. The obtained data were analyzed using Cell Quest software (Becton Dickinson, San Jose, USA).

RNA extraction and RT-PCR
Total RNA was extracted from the cells by means of Trizol reagent following the manufacturer’s protocol. The RNA concentration, quantity, and quality were confirmed by a spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA) using the relative absorbance ratio at 260/280. For the cDNA synthesis, 1 µg of isolated RNAs and 0.5 µM (20 pmol) primer hexamer were made to reach 12.5 µl with diethylpyrocarbonate (DEPC)-treated water, and then, incubated at 65 °C for 5 min and kept on ice for 1 min. Afterward, 2 µl (1 mM final concentration) of the dNTPs mix, 2 µl 10X reaction buffer, 1 U/µl reverse transcriptase (mM LV), and 0.5
U/µl RNase inhibitor were added, and then, 20 µl total volume of reaction was reached with DEPC-treated water. The reverse transcription condition was as follows: 25 °C for 10 min and 42 °C for 60 min and 75 °C for 5 min (14).

Quantification of gene expression by qPCR analysis
The quantitative expression of mRNA of the target genes was accomplished by means of SYBR® Green Master Mix on Bio-Rad IQ5 Cycler (Bio-Rad, Hercules, CA, USA). Table 1 represents the sequences of primers used in this investigation. The qPCR was fulfilled as 20 µl reaction, containing 1 µl cDNA, 10 µl of Power SYBR Green PCR Master Mix (2X), 0.2 µM from each forward and reverse primers and 8.9 μl DEPC-treated water. The PCR reaction was done based on a cycle, including 95 °C for 30 sec, followed by 40 cycles of denaturation at 94 °C for 15 sec, annealing at 60 °C for 30 sec and extension at 72 °C for 30 sec. The endogenous control GAPDH (house-keeping gene) was used for the normalization of the differences in the efficiency of RT. All experiments were repeated in triplicate (15).

Western blotting analysis
The total protein was extracted from the HT29 cells using the PEB solution (i.e., 50 mM Na₂HPO₄, pH 7.0, 10 mM Na₂EDTA, 2 mM β-mercaptoethanol, and 2 mM phenylmethylsulfonyl fluoride). Then, 30 µg of the extracted proteins was exposed to 12% SDS-PAGE gel. Afterward, the proteins were transferred electrophoretically to a nitrocellulose membrane and run on a semi-dry blotting system (Bio-Rad, Hercules, CA, USA). The membranes were then blocked with nonfat skim milk 5% for 12 hr. Subsequently, the membrane was incubated with the designated primary antibodies (using a 1:1000 dilution) and detected by the secondary rabbit anti-human IgG-alkaline phosphatase conjugate (1:1000) (16).

Table 1. The sequences of primers used in the qPCR procedure for analysis of various genes

| Gene name | Primer sequence (forward)       | Primer sequence (reverse)       |
|-----------|---------------------------------|---------------------------------|
| PTEN      | TCCCAGTCAGAGGCGCTATG            | CACAAACTGAGATTGTCAGAG          |
| AKT1      | CATCACACCACCTGCAAAT             | CTCAAATGACCACAGAAAAT           |
| Bax       | CAACACGACAAATTTGACATT          | TCTGTGCTTTTGGACL              |
| Bcl-xl    | GTCCTCGCTTCTTCTTCC              | TACCAGTCAGAGGTCAGG             |
| GAPDH     | AAGCTCATTCTAGTGATGAGG           | TCTGCCTTGTGCTGCTGAG           |

Statistical analysis
In this study, data were presented as the mean values with standard deviation (S.D.), which were obtained from at least three independent experiments. Student’s t-test and one-way ANOVA were utilized for the statistical analysis. A P-value of less than 0.05 was considered statistically significant.

Results
Evaluation of treated cell morphology by CM
In the first step, the HT-29 cells were treated by different amounts (OD₆₀₀: 0.5, 1.0) of CM for 24 and 48 hr. As shown in Figure 1, obvious change was observed in the cell morphology by using light microscopy imaging in (OD₆₀₀: 1.0) after 48 hr, but no clear alteration was seen with CM (OD₆₀₀: 0.5) after 24 hr incubation (Figure S1, supplementary data).

MTT assay
MTT assay showed the potential cytotoxic effect of EcN on HT-29 cells. For this purpose, the HT-29 cells were treated by various amounts (OD₆₀₀: 0.5, 0.75 and 1.0) of CM and HIB for 24 and 48 hr. As presented in Figure 2, the results indicated that both treatments (CM and HIB) reduced viable cell number significantly (P<0.05) after 24 hr in (OD₆₀₀: 1.0) and too significantly (P<0.01) after 48 hr in (OD₆₀₀: 1.0). Thus, it can be deduced that EcN might affect the HT-29 cells. Such effect appeared to occur through a dose- and time-dependent mechanism.

DNA fragmentation assay
Following the MTT results, the DNA fragmentation analysis was performed in the HT-29 cells treated with the CM after 24 and 48 hr. A 100 bp DNA ladder was used to verify the DNA pattern in the gel electrophoresis. In agreement with the MTT results, an apparent DNA breakage was observed after 48 hr, but not after 24 hr treatment with CM (Figure 3).

Figure 1. Morphological changes of HT-29 cells. The cells were treated with CM and observed under light microscopy (10X). (A) Untreated HT-29 cells (control), (B) HT-29 cells treated with CM (OD₆₀₀: 1.0) after 24 hr, and (C) HT-29 cells treated with CM after 48 hr. The cells showed typical features of apoptosis including nuclear fragmentation (NF), membrane blebbing (MB), and cellular shrinkage (CS) in Figure 1C. CM: Conditioned-media
DAPI staining

DAPI staining was carried out for the analysis of morphological changes in the nucleus. The results, in comparison with the untreated control cells (Figure 4A), displayed a substantial fragmentation and changes in the nucleus of the treated cells with CM (Figure 4B) and HIB (Figure 4C) after 48 hr.

Annexin V for the analysis of apoptosis

For the differentiation of the necrotic and apoptotic cells from the healthy cells, annexin V (a phospholipid-binding protein that interacts with the externalized phosphatidylserine (PS) of the plasma membrane after apoptosis) based flow cytometry assay was performed. In comparison with the untreated control cells (Figure 4D), after 48 hr, apoptosis/necrosis was induced in the HT-29 cell treated with CM showing 5.46% and 61.14% early and late apoptosis, respectively, and 13.70% necrosis (Figure 4E). Likewise, we observed 36.39% and 32.13% early and late apoptosis, respectively, and 11.00% necrosis in the HT-29 cells treated with HIB (Figure 4F) after 48 hr.

Apoptosis signaling pathway regulation by EcN

The Bax/Bcl-xL-triggered apoptosis via the mitochondrial pathway and AKT is involved in many cell functions, which can disrupt the balance of apoptosis...
and is negatively regulated by PTEN. To study the effect of EcN on the HT-29 cell signaling pathways, the impacts of both treatments (CM and HIB) were assessed after 48 hr. Based on the qPCR analysis, as shown in Figure 5, in the cells treated with either CM or HIB, the expression of the AKT1 gene (panel A) was down-regulated, while the expressions of PTEN and Bax genes (panels B and C, respectively) were up-regulated. Similarly, the expression of Bcl-xL was found to be slightly enhanced in the cells treated with CM (panel D). The relative expression ratio of Bax/Bcl-xL was significantly higher in the treated cells with either CM or HIB (Figures 5E and F). Likewise, the Western blot analysis confirmed the down-regulation of AKT1 and up-regulation of PTEN and Bax proteins in the cells treated with either CM or HIB as compared with GAPDH as the control (Figure 6).

Figure 5. The real-time PCR analysis HT-29 cells treated with CM or HIB. The cells were treated and analyzed after 48 hr. Panels A, B, C, and D represent the mRNA expression of AKT, PTEN, Bax, and Bcl-xL, respectively. Panels E and F show the Bax/Bcl-xL expression ratio in the cells treated with CM or HIB, respectively. Data expressed as fold change. CT: Control; CM: Condition-media; HIB: Heat-inactivated bacteria. Data are presented as mean SD * and **. P<0.05 (*) and P<0.01 (**)
Discussion

The human gastrointestinal tract comprises a variety of complex microorganisms (microbiota) that maintain gut homeostasis (17). The significance of the microbiota interaction/association with the intestinal epithelial cells in several gastrointestinal disorders has already been reported (18, 19). Further, the therapeutic potential of probiotic strains including EcN has been indicated in several in vitro and in vivo intestinal disease models (17, 20, 21). EcN capability to exclusively colonize and replicate in the necrotic tumor tissue through systemic administration in the animal model makes this species a promising probiotic bacteria in the tumor-targeted therapy (22). Furthermore, since diets contribute significantly to the colon cancer risk factors, there exists a continuously increasing interest in the application of probiotics as a non-separable ingredient of foods and the gut microflora in colorectal cancer treatment. In this current work, we studied the anticancer effect of well-studied probiotic strain EcN on the HT-29 colorectal cancer cells by using different methods, including MTT assay, flow cytometry, DNA ladder, DAPI staining, qPCR, and Western blotting. The MTT results showed that both of the treatments (i.e., CM and HIB; OD_{560} ≈ 1.0) could effectively inhibit colon cancer cell proliferation after 48 hr but not after 24 hr (Figures 2B and D). Such a result seems to be consistent with another investigation carried out by J. Boudeau et al., who presented that this strain might interact with the intestinal epithelial cells possibly in a dose- and time-dependent manner (21). Based on the MTT results, in this study, other experiments were performed at (OD_{560}) of 1.0 after 48 hr. Likewise, our results indicated nearly similar effects of EcN treatments (i.e., CM and HIB) on the HT-29 cells. In spite of aggressive methods for cancer treatment, the apoptotic signaling pathway can be targeted through the bacterial-targeted therapy. Prominent evidence has revealed that this process is disturbed during the progression of colon cancer, which is also related to the emergence of resistance to chemotherapy and radiotherapy (23). Hence, better understanding and targeting of this pathway seems to be a rational strategy as an alternative therapy in cancer treatment. In order to view this, we confirmed the induction of apoptosis by means of various techniques like DNA ladder DAPI staining and flow cytometry after 48 hr of EcN treatment. Furthermore, the molecular mechanism of apoptosis induction was investigated by real-time PCR analysis and Western blotting. Gene expression analysis revealed that both treatments of EcN (CM and HIB) could increase PTEN and decrease AKT activity in the treated HT-29 cells as shown in Figures 5A and B. Moreover, these findings were accompanied by Western blot analysis (Figure 6). AKT, which is a serine/threonine kinase, seems to be involved in various biological phenomena, including apoptosis, cell growth, and cell proliferation. Its activation might promote the survival of cancer cells by phosphorylating and disabling significant proteins of the apoptotic pathway, including caspase-9 and Bad, and up-regulation of anti-apoptotic Bcl-2 family proteins (14). The AKT activity is negatively controlled by the tumor suppressor protein, PTEN, which is commonly mutated in most cancer types (24). An association of phosphoinositide-3-kinase (PI3-K)/PTEN/AKT signaling pathway has been reported in the colon cancer by different research groups (25, 26). Since the expressions of AKT and PTEN were shown to be impaired in 60–70% of colorectal cancers, the inhibition of this signaling pathway has been proposed as a potential target in CRC (10). Moreover, PTEN up-regulation and AKT down-regulation were coupled with significant changes in the Bax/Bcl-xL ratio (Figures 5E and F). It should be pointed out that Bcl-xL is an anti-apoptotic, while Bax as a pro-apoptotic protein can associate with the intrinsic (mitochondrial) pathway of apoptosis. The Bcl-xL overexpression is often correlated with cancer aggressiveness and chemoresistance to therapeutics, which is negatively controlled by Bax. The overexpression of Bcl-2 family has been detected in about 30–94% of human CRC (23, 27). Therefore, targeting this pathway by inactivating Bcl-xL and activating Bax seems to be a promising cancer treatment. In our study, both CM and HIB treatments increased the expression of Bax (Figure 5C), which were further confirmed with the Western blot analysis (Figure 6). Besides, despite our expectation, the Bcl-xL expression was increased in the CM treatment (Figure 5D). However, the Bax/Bcl-xL ratio was increased in both treatments of HT-29 cells, resulting in a profound induction of apoptosis. Thus, it can be concluded that this bacterium can elicit apoptosis in the colon cancer HT-29 cells, attributable to (i) up-regulation of PTEN, (ii) down-regulation of AKT, and (iii) some possible alterations in the mitochondrial function(s). These findings are in accordance with the same study that showed EcN supernatants can effectively reduce the viability of Caco-2 cells, to 51% at 48 hr (28). Besides, it has been reported that EcN supernatant and other probiotic-derived factors can significantly decrease cyclooxygenase-2 (COX-2) gene expression (29) whose inhibition was shown to prevent the CRC initiation (30). Some shreds of evidence have shown that probiotics may play a major role in the regulation of cell proliferation and apoptosis. Iyer et al. reported that Lactobacillus reuteri might promote the apoptosis of activated immune cells by enhancing the pro-apoptotic mitogen-activated protein kinase [MAPK] signaling pathway (31). Other studies demonstrated that exopolysaccharide of Lactobacillus acidophilus and Lactobacillus rhamnosus exert antitumorigenic effects against HT-29 colon cancer cells possibly through the indirect induction of Bcl-2 and Bax family (32). In this line, probiotics may inhibit the progression of CRC through multiple pathways, including (i) production of specific enzymes, (ii) anti-inflammatory products, (iii) reactive oxygen species (ROS), (iv) regulation of cell cycle, and (v) apoptosis (33). Inflammation is a key factor that contributed to CRC progress and development (33). It can be estimated that EcN might regulate the expression of AKT by the production of anti-inflammatory products. Likewise, a prominent role of this bacterium in inflammatory disease has been indicated in a number of studies (34-36). Researchers reported that anti-inflammatory drugs (e.g., piroxicam) are able to inhibit PI3K and AKT level in colon cancer elicited by 1,2-dimethylhydrazine (37). Beside, EcN cooperates with the adaptive immune system in induction of γδ T cell apoptosis and reduction of inflammatory response (38, 39). Since metastasis...
remains the leading cause of death in cancer patients (40, 41), we evaluated the influence of EcN (OD₆₀₀ 1.0) CM on the motility of HT29 cells in vitro (Figure S1, supplementary data). Using the scratch assay, no obvious significant difference was observed between the treated cells and the controls in terms of cell motility. However, strong inhibitory effect of *E. coli* on pulmonary metastasis has previously been reported (41). Our finding showed that EcN can induce apoptosis by modulating signaling pathways in the HT-29 CRC cells and exert anticancer effects if administrated in sufficient amount and in time.

**Conclusion**

As a complementary treatment modality, in addition to the aggressive methods in cancer therapy, the use of indigenous bacterial strains could be a promising approach to control colon cancer. Such treatment modality can balance the gut microflora, resulting in intrinsic impacts on gastrointestinal cells. Given the importance of gut microbiota in human health and disease initiation, the useful properties of *E. coli* Nissle 1917 as the probiotic bacteria have been shown in GI disease. While EcN is commercially available (Mutarflor®) for the treatment of some intestinal disorders (e.g., UC, IBD, and CD), its molecular mechanisms (especially anticancer effect) are yet to be fully addressed. To tackle the therapeutic functions of EcN in CRC, in this investigation, we looked at its impacts on colon cancer HT-29 cells. Our findings revealed key information on the signaling pathways by which EcN might exert its pro-apoptotic impacts on the colon cancer cells through up-regulation of PTEN and *Bax* and down-regulation of *AKT1*. Moreover, similar to other probiotic strains, this bacterium might affect other cancers by modulating different signaling pathways. Based on these findings, we propose EcN as complementary medicine in cancer therapy, while further translational studies are required in animal models and human cases to revalidate its therapeutic potential in cancer inhibition and treatment.

**Acknowledgment**

This work was supported by the Research Center for Pharmaceutical Nanotechnology (RCPN) at Tabriz University of Medical Sciences (Tabriz, Iran) and Isfahan University (Isfahan, Iran).

**Conflicts of Interest**

The authors declare that there are no conflicts of interest.

**References**

1. Khiai MA, Safari A, Aghanejad A, Barar J, Rasta SH, Golchin A, et al. Enzyme-conjugated gold nanoparticles for combined enzyme and photothermal therapy of colon cancer cells. Colloids Surf. A Physicochem Eng Asp 2019; 572:333-344.
2. Vahed SZ, Barzegari A, Saadat YR, Goreyshi A, Omidi Y. *Leuconostoc mesenteroides*-derived anticancer pharmaceuticals hinder inflammation and cell survival in colon cancer cells by modulating NF-κB/AKT/PTEN/MAPK pathways. Biomed Pharmacother 2017; 94:1094-1100.
3. Salmanzadeh R, Eskandani M, Mokhtarzadeh A, Vandighamooni S, Ilghami R, Maleki H, et al. Propyl gallate (PG) and tert-butylhydroquinone (TBHQ) may alter the potential anti-cancer behavior of probiotics. Food Biosci 2018; 24:37-45.
4. Schultz M. Clinical use of *E. coli* Nissle 1917 in inflammatory bowel disease. Inflamm Bowel Dis 2008; 14:1012-1018.
5. Jafari B, Rezaie A, Alizadeh S. Isolation and identification of potentially probiotic bacteria from traditional dairy products of Ardabil region in Iran. Ann Biol Res 2011; 2:311-317.
6. Wei MQ, Mengesha A, Good D, Anne J. Bacterial targeted tumour therapy—dawn of a new era. Cancer Lett 2008; 259:16-27.
7. Westendorf AM, Gunzer F, Deppenmeier S, Tapadar D, Hunger JK, Schmidt MA, et al. Intestinal immunity of *Escherichia coli* Nissle 1917: a safe carrier for therapeutic molecules. FEMS Immunol Med Microbiol 2005; 43:373-384.
8. Sharifi S, Barar J, Hejazi MS, Samadi N. Doxorubicin changes bax/Bcl-xL ratio, Caspase-8 and 9 in breast cancer cells. Adv Pharm Bull 2015; 5:351-359.
9. Danielsen SA, Eide PW, Nesbakken A, Guren T, Leithe E, Lothe RA. Portrait of the *PI3K/AKT* pathway in colorectal cancer. Biochim Biophys Acta 2015; 1855:104-121.
10. Pandurangan AK. Potential targets for prevention of colorectal cancer: a focus on *PI3K/AKT/mTOR* and Wnt pathways. Asian Pac J Cancer Prev 2013; 14:2201-2205.
11. Martínez-Maqueda A, Balleus L, Rocio I. HT-29 CRC cell line. The Impact of Food Bioactives on Health: Springer; Cham: 2015. p. 113-124.
12. Van Meerloo J, Kaspers GJ, Cloos J. Cell sensitivity assays: the MTT assay. Methods Mol Biol 2011; 731:237-245.
13. Rahbar Saadat Y, Saedie N, Zununi Vahed S, Barzegari A, Barar J. An update to DNA ladder assay for apoptosis detection. Bioprints 2015; 5:25-28.
14. Rana C, Piplani H, Vaish V, Nehru B, Sanyal SN. Downregulation of *PI3K-AKT/PTEN* pathway and activation of mitochondrial intrinsic apoptosis by Diclofenac and Curcumin in colon cancer: Mol Cell Biochem 2015; 402:225-241.
15. Asoudeh-Fard A, Barzegari A, Dehnad A, Bastani S, Golchin A, Omidi Y. *Lactobacillus plantarum* induces apoptosis in oral cancer KB cells through upregulation of PTEN and downregulation of MAPK signalling pathways. Bioprints 2017; 7:193-198.
16. Dehghani J, Adibkia K, Movafeghi A, Barzegari A, Pourseif MM, Maleki Kakelar H, et al. Stable transformation of *Spirulina (Arthospira) platensis*: a promising microalgae for production of edible vaccines. Appl Microbiol Biotechnol 2018; 102:9267-9278.
17. Gronbach K, Eberle U, Muller M, Olschlager TA, Dobrindt U, Leithauser F, et al. Safety of probiotic *Escherichia coli* Nissle 1917 distinctively modifies the intestinal immunity of the host. Infect Immun 2010; 78:3036-3046.
18. Lin HC, Hsu CH, Chen HL, Chung MY, Hsu JF, Lien RI, et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight preterm infants: a multicenter, randomized, controlled trial. Pediatrics 2008; 122:693-700.
19. Lupp C, Robertson ML, Wickham ME, Sekirov I, Champion OL, Gaylor EC, et al. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of *Enterobacteriaceae*. Cell Host Microbe 2007; 2:119-129.
20. Sturm A, Rilling K, Baumgart DC, Gargas K, Abou-Ghazale T, Raupach B, et al. *Enterobacteriaceae* modulates T-cell cycling and expansion via toll-like receptor 2 signaling. Infect Immun 2005; 73:1452-1465.
21. Boudeau J, Glasser AL, Julien S, Colombel JF, Darfeuille-Michaud A. Inhibitory effect of probiotic *Escherichia coli* strain Nissle 1917 on adhesion to and invasion of intestinal epithelial cells by adherent-invasive *E. coli* strains isolated from patients with Crohn’s disease. Aliment Pharmacol Ther 2003; 18:45-56.
22. Stritzker J, Weibel S, Hill PJ, Oelschlager TA, Goebel W,
Szalay AA. Tumor-specific colonization, tissue distribution, and gene induction by probiotic *Escherichia coli* Nissle 1917 in live mice. Int J Med Microbiol 2007; 297:151-162.

23. Abrahah AM, Ketema EB. Apoptotic pathways as a therapeutic target for colorectal cancer treatment. World J Gastrointest Oncol 2016; 8:583-591.

24. Parsons R. Human cancer, PTEN and the PI-3 kinase pathway. Semin Cell Dev Biol 2004; 15:171-176.

25. Palozza P, Torelli C, Boninsegna A, Simone R, Catalano A, Mele MC, et al. Growth-inhibitory effects of the astaxanthin-rich alga *Haematococcus pluvialis* in human colon cancer cells. Cancer Lett 2009; 283:108-117.

26. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009; 9:550-562.

27. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010; 138:2073-2087 e2073.

28. Wang H, Bastian SE, Laurence A, Howarth GS. Factors derived from *Escherichia coli* Nissle 1917, grown in different growth media, enhance cell death in a model of 5-fluorouracil-induced caco-2 intestinal epithelial cell damage. Nutr. Cancer 2015; 67:316-326.

29. Otte J-M, Mahjurian-Namari R, Brand S, Werner I, Schmidt WE, Schmitz F. Probiotics regulate the expression of COX-2 in intestinal epithelial cells. Nutr. Cancer 2008; 61:103-113.

30. Nurmí JT, Puolakkainen PA, Rautonen NE. *Bifidobacterium Lactis* sp. 420 up-regulates cyclooxygenase (Cox)-1 and down-regulates Cox-2 gene expression in a Caco-2 cell culture model. Nutr. Cancer 2005; 51:83-92.

31. Iyer C, Kosters A, Sethi G, Kunnumakkara AB, Aggarwal BB, Versalovic J. Probiotic *Lactobacillus reuteri* promotes TNF-induced apoptosis in human myeloid leukemia-derived cells by modulation of NF-κB and MAPK signalling. Cell Microbiol 2008; 10:1442-1452.

32. Kim Y, Oh S, Yun H, Oh S, Kim S. Cell-bound exopolysaccharide from probiotic bacteria induces autophagic cell death of tumour cells. Lett Appl Microbiol 2010; 51:123-130.

33. Zhu Y, Luo TM, Jobin C, Young HA. Gut microbiota and probiotics in colon tumorigenesis. Cancer Lett 2011; 309:119-127.

34. Souza EL, Elian SD, Paula LM, Garcia CC, Vieira AT, Teixeira MM, et al. *Escherichia coli* strain Nissle 1917 ameliorates experimental colitis by modulating intestinal permeability, the inflammatory response and clinical signs in a faecal transplantation model. J Med Microbiol 2016; 65:201-210.

35. Secher T, Kassem S, Benamar M, Bernard I, Boury M, Barreau F, et al. Oral administration of the probiotic strain *Escherichia coli* Nissle 1917 reduces susceptibility to neuroinflammation and repairs experimental autoimmune encephalomyelitis-induced intestinal barrier dysfunction. Front Immunol 2017; 8:1096.

36. Ghouri YA, Richards DM, Rahimi EF, Krill JT, Jelinek KA, DuPont AW. Systematic review of randomized controlled trials of probiotics, prebiotics, and symbiotics in inflammatory bowel disease. Clin Exp Gastroenterol 2014; 7:473-487.

37. Saini MK, Sanyal SN. PTEN regulates apoptotic cell death through PI3-K/Akt/GSK3beta signaling pathway in DMH induced early colon carcinogenesis in rat. Exp Mol Pathol 2012; 93:135-146.

38. Zhang Y, Zhang Y, Xia L, Zhang X, Ding X, Yan F, et al. *Escherichia coli* Nissle 1917 targets and restrains mouse B16 melanoma and 4T1 breast tumors through expression of azurin protein. Appl Environ Microbiol 2012; 78:7603-7610.

39. Guzy C, Paclik D, Schirbel A, Sonnenborn U, Wiedenmann B, Sturm A. The probiotic *Escherichia coli* strain Nissle 1917 induces gammadelta T cell apoptosis via caspase- and Fas-dependent pathways. Int Immunol 2008; 20:829-840.

40. Fidler IJ. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 2003; 3:453-458.

41. Weibel S, Stritzker J, Eck M, Goebel W, Szalay AA. Colonization of experimental murine breast tumours by *Escherichia coli* K-12 significantly alters the tumour microenvironment. Cell Microbiol 2008; 10:1235-1249.